At 8:30 AM NEWS
This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer.
The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much.
Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news.
At...
EU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe.
Hence, I expect the share price will dip further.
Key Trading Plan:
i) SHORT when it reaches the pull back price at 34.98...
The bad news with Pfizer's clinical trial is great news for traders and investors.
Why? Because the 'bottom' has been gauged by this piece of over the weekend news.
The bad news does not materially affect existing revenue stream and earnings.
The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news...
Inverted H&S
Pennant Breakout
1st Target = 786fib
2nd Target = 50
Support = 618fib @ 35
This content is for informational and educational purposes only. This is not in any way, shape or form financial or trading advice.
Good luck, happy trading and stay chill,
2degreez
Pfizer was in a pretty strong uptrend for a while until it suddenly started waffling and then dumped. Wouldn't be surprised to see it pop from here, eventually. It's not exactly a fast moving stock.
🧑⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of...
Technical Analysis:
Wait that the upper resistance line will be broken before buying.
The prices are in a sideways trend, theoretically they should resume their previous trend (uptrend) breaking the top resistance dotted line.
Fundamental Analysis:
Pharmaceutical giant Pfizer (NYSE:PFE), which is working alongside German drugmaker BioNTech (NASDAQ:BNTX) to...
4H Chart Explanation:
- Price bounced on the Support Zone and returned to the Weekly Ascending Trendline.
- Now, it has potential to move up towards the Descending Trendline.
- If price breaks it, there is potential to move up towards the Resistance Zone.
Weekly Vision:
Daily Vision:
Updates coming soon!
SO Moderna spiked from roughly $19.07 to $28 est. in less than 45 minutes after rumors broke into confirmations ending with headlines as Mordova has officially announced a vaccination for COVID-19 has been developed yet with months of red tape ahead of us (still have yet to undergo animal testing, clinical trials, human testing, then once the vaccination has been...
The downwards pattern in the RSI suggest we may break that trend soon and move upwards. Also there is strong support around $27.85 if the downwards trend on the RSI continues and the price hits $27.85 I think there is a buying opportunity but we also see there is resistance on the upside at $37.37ish. Not a bad time to long Pfizer specially if we get close to the...
4H Chart Explanation:
- Price broke the Weekly Ascending Trendline and went down to the Support Zone.
- Price bounced from there, developing a Pullback.
- After the up correction is finished, price wil go down to the next Support Zones.
Weekly Vision:
Daily Vision:
